Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Assessment of Early Changes in SD-OCT After Initiation of a Treatment by Intravitreal Aflibercept (EYLEA®) (2mg) Over a 12-week Period for Patients Suffering From Neovascular Age-related Macular Degeneration (AMD) French SD OCT in wAMD

NCT02246829 is registered in ClinicalTrials.gov with University Hospital, Bordeaux as lead sponsor.

NCT NCT02246829
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02246829 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Assessment of Early Changes in SD-OCT After Initiation of a Treatment by Intravitreal Aflibercept (EYLEA®) (2mg) Over a 12-week Period for Patients Suffering From Neovascular Age-related Macular Degeneration (AMD) French SD OCT in wAMD
Lead sponsor
University Hospital, Bordeaux
Phase
Phase 4
Overall status
Completed
Start date
September 30, 2014
Completion date
June 30, 2015
Enrollment
50 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

neovascular age-related macular degeneration of all subtypes